Study Population The population eligible for inclusion was adults (aged 18.0 years) with both CKD (stage 24 or stage unspecified) and type 2 diabetes who initiated either an SGLT2i or GLP-1 RA in the later period (9 July 2021 [i.e., the FDA approval date of finerenone] to 30 September 2023) with at least 12 months of continuous enrollment before medication initiation (ESM Fig
Shi, S., Kanasaki, K
I started by cutting out carb-rich foods, which included pizza, french fries, bread, pancakes, muffins, cookies, juice, milk, and even high-carb fruits like apples and bananas
"Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over." Current Obesity Reports
Their GLP-1 injectible options include Wegovy/Ozempic, Mounjaro/Zepbound, and Saxenda/Victoza
45 All studies that demonstrated a reduction in MACE on GLP-1RA therapy consistently involved patients with T2D